Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

A Phase III Study of AND017 to Evaluate Efficacy and Safety in NDD-CKD Associated Anemia

15 listopada 2026 zaktualizowane przez: Kind Pharmaceuticals LLC

A Phase 3, Multi-center, Randomized, Open-Label, Active-Controlled, Efficacy and Safety Study of AND017 to Treat Anemia in Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) Patients

This is a Phase 3, randomized, open-label, active-controlled study to evaluate the efficacy and safety of AND017 in non-dialysis-dependent (NDD)-CKD patients with anemia compared with the active control, erythropoietin stimulating agents (ESA).

Przegląd badań

Status

Jeszcze nie rekrutacja

Warunki

Interwencja / Leczenie

Typ studiów

Interwencyjne

Zapisy (Szacowany)

240

Faza

  • Faza 3

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  • Capable of providing signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

  • Body weight from 45-140 kg inclusive.

  • A diagnosis of CKD confirmed at screening, CKD stage 3, 4, or 5 defined by eGFR <60 mL/min/1.73 m2.

  • Prior ESA use and Hb levels:

    1. ESA-naïve: Defined as no use of any ESA treatment for at least 12 weeks before randomization; Mean of the two most recent Hb values during the screening period obtained at least 7 days apart must be ≥7.5 g/dL and <10.0 g/dL.
    2. ESA-treated: Defined as having received an approved ESA, administered intravenously or subcutaneously, for at least 6 weeks prior to randomization, with no change in ESA product and no treatment interruption exceeding two consecutive weeks; Mean of the two most recent Hb values during the screening period obtained at least 7 days apart must be 9.0-11.0 g/dL inclusive.
  • TSAT ≥20% or ferritin ≥100 ng/mL at screening test.

  • Serum folate and vitamin B12 ≥ lower limit normal (LLN) at screening test

  • Total bilirubin ≤1.5× upper limit normal (ULN). For Gilbert's Syndrom, <3×ULN.

  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3×ULN

  • No evidence of other causes of anemia caused by a pathologic process in the hematopoietic system, including intra- or extravascular hemolysis, or myelodysplasia

  • No other primary cause for anemia other than CKD.

Exclusion Criteria:

  • Concurrent retinal neovascular lesions requiring treatment including proliferative diabetic retinopathy, exudative age-related macular degeneration, retinal vein occlusion, macular edema, etc.
  • Chronic inflammatory disease other than glomerulonephritis that could impact erythropoiesis or concurrent autoimmune disease with inflammatory symptoms.
  • History of gastric/intestinal resection considered to affect the absorption of drugs in the gastrointestinal tract or concurrent symptomatic gastroparesis despite being on treatment.
  • Clinically significant bleeding within 4 weeks of first dose; bleeding diathesis or risk of bleeding that has not been medically or surgically corrected at least 4 weeks prior to first dose of study drug.
  • History or concurrent hemosiderosis, hemochromatosis or hyper-coagulable condition.
  • Uncontrolled hypertension, defined as patients with hypertension having more than one of three systolic blood pressure (SBP) >180 mmHg, or diastolic blood pressure (DBP) >110 mmHg during the screening period.
  • History of stroke, transient ischemic attack, myocardial infarction, thromboembolic event , pulmonary embolism, or lung infarction within 24 weeks before the screening assessment.
  • Participants with a history of significant liver disease or active liver disease.
  • History of a seizure disorder or any occurrence of seizures in the past.
  • History or concurrent malignancy, except for cancers determined to be cured or in remission for ≥5 years, curatively resected basal cell or squamous cell carcinoma, cervical cancer in situ.
  • History of a seizure disorder or any occurrence of seizures in the past.
  • History or concurrent malignancy, except for cancers determined to be cured or in remission for ≥5 years, curatively resected basal cell or squamous cell carcinoma, cervical cancer in situ.
  • Having undergone blood transfusion and/or a surgical procedure that caused major blood loss within 8 weeks before the screening assessment
  • Participants that have major surgery planned during the study period.
  • Any prior functioning organ transplant or a scheduled organ transplantation, or anephric.
  • Serum albumin (ALB) < 2.5 g/dL at screening test.
  • Positive for hepatitis B surface antigen or anti-hepatitis C virus antibody at the screening assessment, or positive for human immunodeficiency virus in a past test.
  • Having received any investigational drug in an interventional clinical trial within 5 weeks before the randomization.
  • A known history of allergic reactions to ESA treatment.
  • History of serious drug allergies.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: AND017

AND017 capsules administered orally with a starting dose of 8 mg TIW for ESA naive patients or 10 mg TIW for ESA treated patients

Aktywny komparator: ESA

ESA injection and dose based on package insert and local practice

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
The mean Hb levels averaged over Week 25-29
Ramy czasowe: Week 25 to Week 29

Evaluate the efficacy of AND017 for treatment of anemia in patients with NDD-CKD

Week 25 to Week 29

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Percentage of responders over the main treatment period
Ramy czasowe: Baseline, at Week 1,3, 5, 7, 9, 13, 17, 21, 25, 29 or end of treatment

defined as patients who meet either of the following criteria: For patients with baseline Hb 9.0 g/dL: mean Hb ≥ 10.0 g/dL during Weeks 25-29 and a change from baseline ≥ -1.0 g/dL during Weeks 25-29; For patients with baseline Hb < 9.0 g/dL: an increase in Hb from baseline ≥ 1.0 g/dL during Weeks 3-29

Baseline, at Week 1,3, 5, 7, 9, 13, 17, 21, 25, 29 or end of treatment
Percentage of patients with mean Hb ≥ 10.0 g/dL averaged over Weeks 5-29
Ramy czasowe: Week 5, 7, 9, 13, 17, 21, 25, 29 or end of treatment

Percentage of patients with mean Hb ≥ 10.0 g/dL averaged over Weeks 5-29

Week 5, 7, 9, 13, 17, 21, 25, 29 or end of treatment
The percentage of response visits over the entire study treatment
Ramy czasowe: Week 1,3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment

Response visit is defined as after first reaching ≥ 10.0 g/dL, Hb maintained within the target range of 10.0-11.0 g/dL

Week 1,3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
The cumulative incidence of Hb non-response over Weeks 5-29
Ramy czasowe: Baseline, Week 5, 7, 9, 13, 17, 21, 25, 29 or end of treatment

Non-response is defined as Hb < 10.0 g/dL and an increase from baseline < 1.0 g/dL

Baseline, Week 5, 7, 9, 13, 17, 21, 25, 29 or end of treatment
Change from baseline in serum iron over the entire treatment period
Ramy czasowe: Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Change from baseline in ferritin over the entire treatment period
Ramy czasowe: Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Change from baseline in transferrin over the entire treatment period
Ramy czasowe: Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Change from baseline in transferrin saturation over the entire treatment period
Ramy czasowe: Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Change from baseline in total iron binding capacity over the entire treatment period
Ramy czasowe: Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
The percentage of patients received intravenous iron treatment during the entire study
Ramy czasowe: Week 1,3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Week 1,3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
During the entire treatment period, the mean weekly dose of intravenous iron treatment (mg)
Ramy czasowe: Week 1,3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Week 1,3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
During the entire treatment period, the time to first initiation of intravenous iron treatment (Day)
Ramy czasowe: Week 1,3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Week 1,3, 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Change from baseline in total cholesterol over the entire treatment period
Ramy czasowe: Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Change from baseline in low density lipoprotein over the entire treatment period
Ramy czasowe: Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Change from baseline in high density lipoprotein over the entire treatment period
Ramy czasowe: Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Change from baseline in triglycerides over the entire treatment period
Ramy czasowe: Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment
Baseline, at Week 5, 7, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, and 53 or end of treatment

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Szacowany)

1 lutego 2027

Zakończenie podstawowe (Szacowany)

1 grudnia 2027

Ukończenie studiów (Szacowany)

1 czerwca 2028

Daty rejestracji na studia

Pierwszy przesłany

15 listopada 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

15 listopada 2026

Pierwszy wysłany (Rzeczywisty)

20 listopada 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

20 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

15 listopada 2026

Ostatnia weryfikacja

1 listopada 2026

Więcej informacji

Terminy związane z tym badaniem

Inne numery identyfikacyjne badania

  • AND017-US-303

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIE

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Tak

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .